Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
556 stopped studies mapped to Acute Myeloid Leukemia and descendants · 90% state a reason
Over the 556 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03603964 | Guadecitabine Extension Study | Phase 2 | terminated | Jul 27, 2018 | Astex Pharmaceuticals, Inc. | Early termination not due to patient safety | Safety / toxicity |
| NCT05569512 | Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation… | Phase 1 | terminated | Oct 6, 2022 | Malika Kapadia | On 7/26/24 the Sponsor-Investigator was notified GlycoMimetics was terminating contracting for… | Investigator |
| NCT06007911 | Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With… | Phase 1 | withdrawn | Aug 23, 2023 | Medical College of Wisconsin | Sponsor withdrew support. | Other (stated, no rule matched) |
| NCT02353143 | Study of MEN1112 Intravenous Infusion in Relapsed or Refractory Acute Myeloid Leukemia(ARMY) | Phase 1 | terminated | Feb 2, 2015 | Menarini Group | The Sponsor accepted the iDSMB recommendation to terminate the study due to evidence of… | Safety / toxicity |
| NCT05028751 | A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants… | Phase 1 / Phase 2 | terminated | Aug 31, 2021 | Kronos Bio | Sponsor decision | Sponsor / business decision |
| NCT05622591 | ELU001 in Pediatric Subjects Who Have Relapsed and/or Refractory CBFA2T3-GLIS2-positive…(Pediatric AML) | Phase 1 | withdrawn | Nov 18, 2022 | Elucida Oncology | Lack of Funding - no safety issue with Drug; Company Permanently Closed | Safety / toxicity |
| NCT00522990 | Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias | Phase 1 / Phase 2 | terminated | Aug 30, 2007 | Astex Pharmaceuticals, Inc. | Recommended Phase II dose determined | Other (stated, no rule matched) |
| NCT04155580 | A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With… | Phase 1 | terminated | Nov 7, 2019 | Astex Pharmaceuticals, Inc. | Study halted prematurely and will not resume; participants are no longer being examined or… | Other (stated, no rule matched) |
| NCT04637009 | A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML)… | Phase 1 | terminated | Nov 19, 2020 | Astex Pharmaceuticals, Inc. | termination due to portfolio prioritization | Sponsor / business decision |
| NCT03318016 | Arsenic Trioxide With Cyclophosphamide in Patients With Relapsed/Refractory Acute Myeloid… | Phase 1 | terminated | Oct 23, 2017 | University of Colorado, Denver | Low enrollment, University Scientific Review Committee required study closure. | Enrollment / accrual |
| NCT03616470 | Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With… | Phase 3 | terminated | Aug 6, 2018 | GlycoMimetics Incorporated | Trial failed to meet primary endpoint. | Other (stated, no rule matched) |
| NCT03198234 | Use of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood Disorders(T-allo10) | Phase 1 | terminated | Jun 26, 2017 | Roncarolo, Maria Grazia, MD | Lack of Enrollment | Enrollment / accrual |
| NCT03088709 | Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide | Phase 2 | terminated | Mar 23, 2017 | Loyola University | Poor accrual | Enrollment / accrual |
| NCT06337331 | Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic… | Phase 2 | withdrawn | Mar 29, 2024 | Northside Hospital, Inc. | Unable to accommodate FDA recommendations for protocol revisions | Other (stated, no rule matched) |
| NCT04172844 | Pevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients…(PAVE) | Phase 1 | terminated | Nov 21, 2019 | Medical College of Wisconsin | Takeda P3001 study didn't meet primary endpoint of improvement in event-free survival. There is no… | Other (stated, no rule matched) |
| NCT04526288 | CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade… | Phase 2 | terminated | Aug 25, 2020 | Fred Hutchinson Cancer Center | Terminated due to low accrual | Enrollment / accrual |
| NCT00346632 | An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and… | Phase 1 | terminated | Jun 30, 2006 | Kyowa Kirin, Inc. | Terminated due to suboptimal dosing schedule | Other (stated, no rule matched) |
| NCT02942758 | Low-dose AZA, Pioglitazone, ATRA Versus Standard-dose AZA in Patients >=60 Years With…(AML-ViVA) | Phase 2 | terminated | Oct 24, 2016 | University Hospital Regensburg | Due to financial reasons. | Funding |
| NCT02181699 | Study of KHK2823 in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic… | Phase 1 | terminated | Jul 4, 2014 | Kyowa Kirin, Inc. | Failed treatment response | Other (stated, no rule matched) |
| NCT05895201 | High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the… | Phase 1 / Phase 2 | withdrawn | Jun 8, 2023 | Indiana University | PI has left IU with no plan to initiate study at IU | Other (stated, no rule matched) |
| NCT00779480 | Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute… | Phase 1 | terminated | Oct 24, 2008 | Kyowa Kirin Co., Ltd. | Failure to demonstrate a tolerable dose that had potential for efficacy. | Efficacy / futility |
| NCT04571645 | Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid…(AML) | Phase 3 | terminated | Oct 1, 2020 | Jazz Pharmaceuticals | Study enrollment was terminated on 16 May 2022 due to slow recruitment. | Enrollment / accrual |
| NCT06362031 | A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource… | — | withdrawn | Apr 12, 2024 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT05367401 | A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS… | Phase 1 / Phase 2 | withdrawn | May 10, 2022 | Novartis Pharmaceuticals | waiting for update from Study Lead | Other (stated, no rule matched) |
| NCT02446145 | A Randomized Placebo-controlled Phase 2 Study of Decitabine With or Without Eltrombopag…(DELTA) | Phase 2 | terminated | May 18, 2015 | Technische Universität Dresden | Due to COVID-19 pandemia, recruitment was insufficient to reach required sample size in an… | COVID-19 / pandemic |
| NCT04113616 | An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When… | Phase 1 / Phase 2 | terminated | Oct 3, 2019 | Kartos Therapeutics, Inc. | In September 2023, the study was terminated because of a Sponsor decision, unrelated to safety… | Safety / toxicity |
| NCT05720988 | Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid… | Phase 1 | withdrawn | Feb 9, 2023 | Jonsson Comprehensive Cancer Center | trial was not opened | Other (stated, no rule matched) |
| NCT03878524 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME… | Phase 1 | terminated | Mar 18, 2019 | OHSU Knight Cancer Institute | Low accrual | Enrollment / accrual |
| NCT04912063 | Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used… | Phase 1 | terminated | Jun 3, 2021 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT05345938 | A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid… | Phase 1 / Phase 2 | terminated | Apr 26, 2022 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Adjust the research strategy. | Sponsor / business decision |
| NCT02508324 | IPA Targeted Adoptive Immunotherapy vs Adult Haplo-identical Cell Infusion During… | Phase 2 | terminated | Jul 24, 2015 | Weill Medical College of Cornell University | Slow accrual and change in direction of cord blood program | Enrollment / accrual |
| NCT04956042 | Study of Fosciclopirox in Patients With Relapsed/Refractory Acute Myeloid Leukemia | Phase 1 / Phase 2 | terminated | Jul 9, 2021 | CicloMed LLC | Discontinued | Other (stated, no rule matched) |
| NCT05829434 | Magrolimab Plus Intensive Chemotherapy in Newly Diagnosed AML or HR-MDS(MAGROLIC) | Phase 2 | withdrawn | Apr 25, 2023 | Uwe Platzbecker | Trial was stopped prematurely due to safety reasons | Safety / toxicity |
| NCT05107856 | PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or… | Phase 1 | terminated | Nov 4, 2021 | Prelude Therapeutics | Company Decision | Sponsor / business decision |
| NCT02152956 | Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid…(VOYAGE) | Phase 1 / Phase 2 | terminated | Jun 2, 2014 | MacroGenics | Business decision | Sponsor / business decision |
| NCT04092179 | Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers | Phase 1 / Phase 2 | terminated | Sep 17, 2019 | University Health Network, Toronto | Insufficient Funding | Funding |
| NCT04996030 | A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia | Phase 1 | suspended | Aug 9, 2021 | Syros Pharmaceuticals | Prioritization | Other (stated, no rule matched) |
| NCT04196010 | Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory… | Phase 1 | terminated | Dec 12, 2019 | University of Washington | Terminated due to unfavorable risk-benefit ratio of investigational regimen. | Other (stated, no rule matched) |
| NCT05066165 | Study Investigating NTLA-5001 in Subjects With Acute Myeloid Leukemia | Phase 1 / Phase 2 | terminated | Oct 4, 2021 | Intellia Therapeutics | Pivoting to an allogeneic version of this program currently in preclinical development. | Other (stated, no rule matched) |
| NCT06180863 | Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid… | Phase 2 | withdrawn | Dec 26, 2023 | Yale University | Lack of funding. | Funding |
| NCT05201183 | A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI)… | Phase 1 / Phase 2 | withdrawn | Jan 21, 2022 | Naoyuki G. Saito, M.D., Ph.D. | insufficient staff and updates in standard practice have made it difficult to recruit participants | Enrollment / accrual |
| NCT05321940 | Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive… | Phase 1 | withdrawn | Apr 11, 2022 | Juan C. Ramos, MD | Investigator decision | Investigator |
| NCT00540995 | Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem… | Phase 1 / Phase 2 | terminated | Oct 8, 2007 | City of Hope Medical Center | Unable to safely escalate to TMLI doses that were hypothesized to be effective and less toxic than… | Enrollment / accrual |
| NCT03904251 | CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid… | Phase 1 | terminated | Apr 5, 2019 | Jonsson Comprehensive Cancer Center | slow accrual | Enrollment / accrual |
| NCT02520011 | Alvocidib Biomarker-driven Phase 2 AML Study | Phase 2 | terminated | Aug 11, 2015 | Sumitomo Pharma America, Inc. | Due to slow enrollment, the extensive time projected to conclude the study hypothesis rendered the… | Enrollment / accrual |
| NCT03969420 | Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With… | Phase 2 | terminated | May 31, 2019 | Sumitomo Pharma America, Inc. | Business decision to terminate the development of alvocidib program on 17 November 2020. Patients… | Sponsor / business decision |
| NCT05943314 | Clinical Study on Safety and Efficacy of Anti-CLL1 /+CD33 CAR T Cells in the Treatment of… | N/A | withdrawn | Jul 13, 2023 | Guangzhou Bio-gene Technology Co., Ltd | The clinical trial was terminated due to a change in sponsor strategy. | Sponsor / business decision |
| NCT04023071 | FT516 in Subjects With Advanced Hematologic Malignancies | Phase 1 | terminated | Jul 17, 2019 | Fate Therapeutics | The study was terminated by the Sponsor. | Other (stated, no rule matched) |
| NCT04485052 | Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in… | Phase 1 / Phase 2 | suspended | Jul 24, 2020 | Innovent Biologics (Suzhou) Co. Ltd. | Pause for changes in development strategies | Sponsor / business decision |
| NCT03690154 | A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors… | Phase 1 | terminated | Oct 1, 2018 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Despite demonstrated safety and tolerability the trial was terminated early due to program… | Safety / toxicity |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Aug 27, 2024source: clinicaltrials